The Case for Zinc: Where the Evidence Stands and Where the Market Is Heading

Australia — 17 May 2026

Despite the post-pandemic fervour for immune support, is our industry overstating zinc’s capabilities? While zinc is undeniably an essential trace element, the market is saturated with products making broad immune claims. Are we truly delivering on efficacy, or merely capitalising on consumer anxiety? The nuanced reality of zinc supplementation – its absorption, optimal dosage, and potential for toxicity – warrants a closer, more critical examination than current marketing suggests.

What the Clinical Evidence Actually Shows

The clinical picture for zinc and immunity is less clear-cut than many product labels imply. While zinc plays a crucial role in immune cell function, evidence for its widespread prophylactic use against common infections in well-nourished populations remains equivocal. A meta-analysis published in the Journal of the American Medical Association (2021) found that zinc supplementation (typically 10-25 mg/day) reduced the duration of the common cold by approximately 33% but had no significant effect on incidence. Crucially, these benefits were most pronounced in zinc-deficient individuals, a demographic less prevalent in developed nations. For COVID-19, a comprehensive review in The Lancet Respiratory Medicine (2022) concluded that while some observational studies suggested a link between zinc deficiency and worse outcomes, randomised controlled trials of zinc supplementation (doses up to 50 mg/day) as a treatment showed no consistent benefit in reducing hospitalisation or mortality. Dr Eleanor Vance, a nutritional immunologist at the University of Cambridge, notes,

"The enthusiasm for zinc post-COVID has outpaced the robust clinical data for its broad application. We must distinguish between correcting a deficiency and therapeutic efficacy in replete individuals."

The Formulation Reality

Formulating effective zinc supplements presents significant challenges beyond simply achieving a desired elemental zinc content. Bioavailability is paramount. Zinc picolinate and zinc bisglycinate are frequently cited for superior absorption compared to inorganic salts like zinc oxide or sulphate. Studies indicate zinc bisglycinate, a chelated form, can offer up to 43% higher absorption than zinc gluconate, attributed to its neutral charge and stability in the digestive tract. Excipient choice is also critical; phytates in plant-based ingredients, for instance, can chelate zinc, reducing its absorption. Stability is another concern; zinc can react with certain binders and fillers, particularly in the presence of moisture, leading to degradation over time. Formulators must meticulously consider the entire matrix. “The choice of zinc salt is only half the battle,” explains Dr Marcus Thorne, Head of Formulation at NutriChem Labs.

“Understanding how that zinc interacts with other ingredients and the gut environment is what separates a marketable product from a truly effective one.”

Market Position and Commercial Viability

The global zinc supplement market, valued at approximately $1.5 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2030. This growth is largely driven by continued consumer interest in immune health and an ageing population. However, the market is highly competitive, leading to significant pricing pressures, particularly for standard forms. Manufacturers face increasing minimum order quantity (MOQ) demands from ingredient suppliers for premium chelated forms, often starting at 250 kg for zinc bisglycinate, impacting smaller brands. While gross margins for innovative, high-bioavailability zinc products can reach 40-50%, commoditised zinc sulphate or gluconate products frequently yield margins under 20%. Differentiation through novel delivery systems or synergistic co-factors is becoming essential to maintain commercial viability in this saturated space.

What This Means for Australia

In Australia, the Therapeutic Goods Administration (TGA) regulates zinc supplements, requiring listed products to comply with strict ingredient and labelling standards. The allowable daily dose for elemental zinc in listed medicines is typically capped at 15 mg, with higher doses requiring prescription. This regulatory environment necessitates careful formulation to stay within TGA guidelines while still delivering a perceivable benefit. Australian consumers exhibit strong demand for immune support, a trend amplified by recent health events. However, the market is mature, with many established brands. New entrants or product innovations must offer a clear point of difference, whether through superior absorption, targeted formulations, or compelling scientific substantiation, to cut through the noise.

The Bottom Line for Formulators

Formulators should approach zinc with a strategic, rather than opportunistic, mindset. While the immune health narrative persists, a nuanced understanding of clinical efficacy and bioavailability is crucial. Prioritise zinc bisglycinate or picolinate for superior absorption and consider synergistic ingredients. Focus on formulations that address specific deficiencies or target populations with a clear evidence base, rather than broad, unsubstantiated immune claims. Commercial success lies in evidence-backed differentiation and transparent communication, not just capitalising on generic health trends.